MarketPulse

mRNA technology

6 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer vs. Moderna: Navigating Pharma's Post-Pandemic Pivot

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.
MRKPFEMRNAbiotechclinical trials
BenzingaBenzinga··Vandana Singh

BioNTech Plummets 14% as Co-Founders Exit for New mRNA Venture

BioNTech shares plunge 14% as co-founders announce exit plan, with company cutting 2026 revenue guidance due to declining COVID demand.
BMYCELGrPFEMRNABNTXguidance reductionPhase 3 trials
BenzingaBenzinga··Vandana Singh

Moderna Settles $950M Patent Dispute, Clears Path for Profitability Push

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.
MRNABNTXROIVABUSbalance sheet strengthmRNA technology
The Motley FoolThe Motley Fool··Adria Cimino

Moderna Charts Post-Pandemic Course With Pipeline Diversification Strategy

Moderna shifts from pandemic revenues toward diversified pipeline including seasonal vaccines and oncology treatments, targeting cash breakeven by 2028 amid FDA progress on flu vaccine candidate.
MRNAFDA approvalmRNA technology
The Motley FoolThe Motley Fool··Adria Cimino

Coatue Management Exits CoreWeave While Establishing Moderna Position

Coatue Management exited CoreWeave with 80% gains, reallocating capital toward a new Moderna position ahead of the biotech stock's 50% rally.
CRWVTSMMRNAportfolio rebalancing13F filings
BenzingaBenzinga··Vandana Singh

BioNTech Sues Moderna Over Patent Rights to Next-Gen COVID Vaccine

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.
PFEMRNABNTXintellectual propertymRNA technology